Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

G-CSF ADMINISTRATION IN 27 CHEMOTHERAPY PATIENTS

Executive Summary

G-CSF ADMINISTRATION IN 27 CHEMOTHERAPY PATIENTS at Memorial Sloan-Kettering resulted in a dose-dependent increase in patient neutrophil counts and reduced the number of days antibiotics were needed to treat fever and neutropenia, according to Memorial Sloan-Kettering Cancer Center researcher Janice Gabrilove. The researcher reported the study results at a recent seminar held by the American Cancer Society in Irvine, California. Patients participating in the study had transitional-cell carcinoma of the urothelium. They were given recombinant human granulocyte colony stimulating factor (G-CSF) before and/or during treatment with a chemotherapeutic regimen of methotrexate, doxorubicin, vinblastine and cisplatin. G-CSF treatment was also found to significantly increase the percentage of patients qualified to receive a second course of chemotherapy after two weeks and to significantly decrease the incidence and severity of mucositis. Drug for the study was supplied by Amgen. Gabrilove said her findings suggest that G-CSF has the potential to reduce cancer treatment morbidity, improve patient survival by allowing treatment to be maintained, and increase the maximum tolerated dose by "diminishing the complication of neutropenia." She and her colleagues are presently investigating the role of G-CSF as a primary treatment of myeloid leukemia, and studying non-malignant conditions that might develop from a deficiency of G-CSF. Gabrilove also presented results of the Phase I/II study to the National Institutes of Health's April 17-19 consensus conference on oral complications of chemotherapy. Among other presentations at the American Cancer Society conference, William Dalton, University of Arizona College of Medicine, reported on the use of verapamil (Searle's Calan and Knoll's Isoptin) to overcome drug resistance in patients with myeloma and non-Hodgkin's lymphoma. Dalton said preliminary results have shown that continuous infusion verapamil, given with the cytotoxic agents doxorubicin and vincristine, "is capable of reversing resistance" in some patients whose tumors overexpress P-glycoprotein. In another presentation, Selwyn Broitman, Boston University School of Medicine, reported that lovastatin (Merck's Mevacor) retarded tumor cell growth by blocking cholesterol synthesis in five out of six human colon tumor cell lines. "These findings imply that it may be possible to inhibit hepatic metastasis from colon tumors with an inhibitor of cholesterol synthesis," such as lovastatin, he stated.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS015462

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel